Can-Fite BioPharma Ltd. (TLV:CANF)
250.10
-11.30 (-4.32%)
Nov 12, 2026, 5:24 PM IST
Can-Fite BioPharma Revenue
Can-Fite BioPharma had revenue of $202.00K USD in the half year ending June 30, 2026, a decrease of -36.08%. This brings the company's total for the last twelve months to $405.00K, down -27.68% year-over-year. In the year 2025, Can-Fite BioPharma had annual revenue of $405.00K, down -39.91%. That makes Can-Fite BioPharma the 44,852nd largest company in the world by revenue and 444th in Israel.
Revenue
$405.00K
Revenue Growth
-27.68%
P/S Ratio
12.57
Revenue / Employee
$81.00K
Employees
5
Market Cap
15.16M ILS
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 405.00K | -269.00K | -39.91% |
| Dec 31, 2024 | 674.00K | -69.00K | -9.29% |
| Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
| Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
| Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
| Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
| Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
| Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
| Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
| Dec 31, 2016 | 165.00K | -200.00 | -0.12% |
| Dec 31, 2015 | 165.20K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 467.66K | -278.63K | -37.34% |
| Dec 31, 2010 | 746.29K | -125.25K | -14.37% |
| Dec 31, 2009 | 871.53K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Can-Fite BioPharma News
- 13 hours ago - Can-Fite's Piclidenoson Cuts Kidney Disease Marker By Up To 80% In Preclinical Study - Nasdaq
- 15 hours ago - Can-Fite's Piclidenoson Demonstrates Up to 80% Improvement in Kidney Disease Marker in Lowe Syndrome Preclinical Study: Published in Nature Portfolio Journal - GlobeNewsWire
- 3 days ago - Can-Fite Highlights Long-Term Outcome From Investigational Liver Cancer Treatment Study - Nasdaq
- 3 days ago - Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study - Nasdaq
- 3 days ago - Can-Fite BioPharma Namodenoson patient reaches 10-year survival in liver cancer - TheFly
- 3 days ago - Can-Fite Reports Ten-Year Survival Milestone for Advanced Liver Cancer Patient from Phase II Namodenoson Study - GlobeNewsWire
- 6 days ago - Can-Fite to Pursue Global Licensing and Strategic Partnerships at BIO-Europe 2026 Following Recent Clinical and Intellectual Property Milestones - GlobeNewsWire
- 10 days ago - Can-Fite Announces Eurasian Patent Allowance Supporting Piclidenoson Development and Commercialization in Lowe Syndrome - GlobeNewsWire